Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 15
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Exploring Plasma Coenzyme Q10 Status in Paediatric Dyslipidaemia

  • Minguez, B.|||0000-0002-7699-3972
  • Paredes-Fuentes, Abraham J.|||0000-0002-7163-2385
  • Oliva, C.
  • Rodriguez-Gonzalez, H.
  • Santos Ocaña, Carlos|||0000-0002-2379-796X
  • Artuch, R.|||0000-0002-3422-9685
  • Santos, Mariela de los
  • Garcia-Volpe, Camila
  • Molera Busoms, Cristina
  • Arias, Angela
  • Yubero, Délia
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Meavilla, Silvia
Coenzyme Q10 (CoQ) is a ubiquitous lipid with different biological functions. In blood, there is a close relationship between CoQ status and cholesterol, which strongly supports the study of both molecules simultaneously. The objective of this study was to evaluate plasma CoQ, lipoprotein concentrations and CoQ/Chol ratio in a cohort of paediatric patients with different types of dyslipidaemias. A total of 60 paediatric patients were recruited (age range: 7 months-18 years), including 52 with different types of hypercholesterolemia, 2 with isolated hypertriglyceridemia and 6 with hypobetalipoproteinemia. Plasma CoQ was analysed by HPLC with electrochemical detection, and lipoprotein and cholesterol concentrations by standard automated methods. The lowest CoQ values were detected in patients with hypobetalipoproteinemia and in two cases of liver cirrhosis. Mean CoQ values were significantly higher in hypercholesterolemic patients compared to controls (average values 1.07 µmol/L and 0.63 µmol/L) while the CoQ/cholesterol ratio did not show differences (170 vs. 163, respectively). Mean CoQ values were significantly lower in the group of patients with hypobetalipoproteinemia compared to controls (mean CoQ values of 0.22 µmol/L vs. 0.63 µmol/L, respectively), while those of CoQ/cholesterol did not show differences. Pearson's correlation test showed a positive correlation between the CoQ and cholesterol values (r = 0.565, p < 0.001) and between the CoQ and the LDL cholesterol values (r = 0.610, p < 0.001). Our results suggest that it is advisable to analyse plasma CoQ and cholesterol concentrations in patients with hypobetalipoproteinemia and hypercholesterolemia associated with liver damage.
Repisalud
Publication Artículo científico (JournalArticle)

How to present economic evaluations to non-technical audiences? Randomized trials with professionals and the general population

  • Linertová, Renata
  • Hernández-Yumar, Aránzazu
  • Guirado-Fuentes, Carmen
  • Rodríguez-Díaz, Benjamín
  • Valcárcel-Nazco, Cristina
  • Imaz-Iglesia, Iñaki
  • Carmona, Montserrat
  • García-Pérez, Lidia
Background: Cost-effectiveness analyses of health technologies have become a part of the decision-making process in healthcare policies. Nevertheless, economic results are not always presented in comprehensible formats for non-technical audiences, such as the general population, healthcare professionals or decision-makers. The purpose of this study was to observe which formats best convey the key message of an economic evaluation, and which are best received by two different audiences. Methods: The summary of a hypothetical cost-effectiveness analysis was edited in different formats: infographic, plain language text and video-abstract for the general population; executive summary and policy brief for a specialized population, i.e. clinicians, clinical and non-clinical managers, or methodologists in health-technology assessment. Participants were randomly shown one of the formats, and data on objective and subjective comprehension, and perceived usefulness/acceptability were gathered by means of online questionnaires. Statistical differences between formats within each audience were analysed. Results: In the general population (N = 324), objective comprehension was statistically significantly better for infographic than for video-abstract (p = 0.005), and for plain text than for video-abstract (p = 0.024). There were no differences in subjective comprehension, but video-abstract was considered statistically significantly more useful to understand the information than plain text (p = 0.011). In the specialized population (N = 100), no statistically significant differences were observed for objective and subjective comprehension, although policy brief was perceived as statistically significantly more useful than executive summary (p = 0.005). Conclusions: A balance between effectivity of conveying the message and attractivity of the format needs to be sought, to facilitate non-technical audiences' understanding of economic data and, consequently, perceive decision-making processes as more transparent and legitimate. The infographic and policy brief could be robust ways to present economic data to the general public and specialized audience, respectively.
Repisalud
Publication Artículo científico (JournalArticle)

Shoc2/Sur8 Protein Regulates Neurite Outgrowth

  • Leon-Espinosa, Gonzalo
  • Sanchez-Ruiloba, Lucia
  • Perez-Rodriguez, Andrea
  • Gragera, Teresa
  • Martinez, Natalia
  • Hernandez, Silvia
  • Anta-Felez, Berta
  • Calero, Olga
  • Garcia-Dominguez, Carlota A
  • Dura, Lara M
  • Peña-Jimenez, Daniel
  • Castro, Judith
  • Zarich-Dimitrievich, Natasha
  • Sánchez-Gómez, Pilar
  • Calero, Miguel
  • Iglesias, Teresa
  • Oliva-Martinez, Jose Luis
  • Rojas-Cabañeros, Jose Maria
The Shoc2 protein has been implicated in the positive regulation of the Ras-ERK pathway by increasing the functional binding interaction between Ras and Raf, leading to increased ERK activity. Here we found that Shoc2 overexpression induced sustained ERK phosphorylation, notably in the case of EGF stimulation, and Shoc2 knockdown inhibited ERK activation. We demonstrate that ectopic overexpression of human Shoc2 in PC12 cells significantly promotes neurite extension in the presence of EGF, a stimulus that induces proliferation rather than differentiation in these cells. Finally, Shoc2 depletion reduces both NGF-induced neurite outgrowth and ERK activation in PC12 cells. Our data indicate that Shoc2 is essential to modulate the Ras-ERK signaling outcome in cell differentiation processes involved in neurite outgrowth.
Repisalud
Publication Artículo de revisión (ReviewArticle)

Brain organoid as a model to study the role of mitochondria in neurodevelopmental disorders: achievements and weaknesses

  • Coronel Lopez, Raquel
  • García-Moreno, Enrique
  • Siendones, Emilio
  • Barrero, Maria
  • Martinez-Delgado, Beatriz
  • Santos-Ocaña, Carlos
  • Liste-Noya, Isabel
  • Cascajo-Almenara, M V
Mitochondrial diseases are a group of severe pathologies that cause complex neurodegenerative disorders for which, in most cases, no therapy or treatment is available. These organelles are critical regulators of both neurogenesis and homeostasis of the neurological system. Consequently, mitochondrial damage or dysfunction can occur as a cause or consequence of neurodevelopmental or neurodegenerative diseases. As genetic knowledge of neurodevelopmental disorders advances, associations have been identified between genes that encode mitochondrial proteins and neurological symptoms, such as neuropathy, encephalomyopathy, ataxia, seizures, and developmental delays, among others. Understanding how mitochondrial dysfunction can alter these processes is essential in researching rare diseases. Three-dimensional (3D) cell cultures, which self-assemble to form specialized structures composed of different cell types, represent an accessible manner to model organogenesis and neurodevelopmental disorders. In particular, brain organoids are revolutionizing the study of mitochondrial-based neurological diseases since they are organ-specific and model-generated from a patient's cell, thereby overcoming some of the limitations of traditional animal and cell models. In this review, we have collected which neurological structures and functions recapitulate in the different types of reported brain organoids, focusing on those generated as models of mitochondrial diseases. In addition to advancements in the generation of brain organoids, techniques, and approaches for studying neuronal structures and physiology, drug screening and drug repositioning studies performed in brain organoids with mitochondrial damage and neurodevelopmental disorders have also been reviewed. This scope review will summarize the evidence on limitations in studying the function and dynamics of mitochondria in brain organoids.
Repisalud
Publication Artículo científico (JournalArticle)

Mammalian son of sevenless Guanine nucleotide exchange factors: old concepts and new perspectives

  • Rojas-Cabañeros, Jose Maria
  • Oliva-Martinez, Jose Luis
  • Santos, Eugenio
The Son of Sevenless (Sos) factors were originally discovered 2 decades ago as specialized Ras activators in signaling pathways controlling the process of R7 cell development in the eye of Drosophila melanogaster. The 2 known members of the mammalian Sos family (Sos1 and Sos2) code for ubiquitously expressed, highly homologous (69% overall) proteins involved in coupling signals originated by cell surface receptor tyrosine kinases (RTKs) to downstream, Ras-dependent mitogenic signaling pathways. Mechanistically, the Sos proteins function as enzymatic factors interacting with Ras proteins in response to upstream stimuli to promote guanine nucleotide exchange (GDP/GTP) and subsequent formation of the active Ras-GTP complex. In this review, we summarize current knowledge on structural, regulatory, and functional aspects of the Sos family, focusing on specific aspects of Sos biology such as structure-function relationship, crosstalk with different signaling pathways, and in vivo functional significance as deduced from phenotypic characterization of Sos knockout mice and human genetic syndromes caused by germline hSos1 mutations.
Repositori Institucional UIB
Publication Artículo científico (JournalArticle)

Evolving spectrum but persistent high mortality of COVID-19 among patients on kidney replacement therapy in the vaccine era: the Spanish COVID-19 KRT

  • Quiroga, B.
  • Ortiz, A.
  • Cabezas, C. J.,
[eng] Background: Kidney replacement therapy (KRT) conferred a high risk for coronavirus disease 2019 (COVID-19) related mortality early in the pandemic. We evaluate the presentation, treatment and outcomes of COVID-19 in patients on KRT over time during the pandemic.<strong>Methods</strong>This registry-based study involved 6080 dialysis and kidney transplant (KT) patients with COVID-19, representing roughly 10% of total Spanish KRT patients. Epidemiology, comorbidity, infection, vaccine status and treatment data were recorded, and predictors of hospital admission, intensive care unit (ICU) admission and mortality were evaluated. Results: Vaccine introduction decreased the number of COVID-19 cases from 1747 to 280 per wave. Of 3856 (64%) COVID-19 KRT patients admitted to the hospital, 1481/3856 (38%) were admitted during the first of six waves. Independent predictors for admission included KT and the first wave. During follow-up, 1207 patients (21%) died, 500/1207 (41%) during the first wave. Among vaccinated patients, mortality was 19%, mostly affecting KT recipients. Overall, independent predictors for mortality were older age, disease severity (lymphopaenia, pneumonia) and ICU rejection. Among patient factors, older age, male sex, diabetes, KT and no angiotensin receptor blockers (ARB) were independent predictors of death. In KT recipients, individual immunosuppressants were independent predictors of death. Over time, patient characteristics evolved and in later pandemic waves, COVID-19 was mainly diagnosed in vaccinated KT recipients; in the few unvaccinated dialysis patients, ICU admissions increased and mortality decreased (28% for the first wave and 16–22% thereafter). Conclusions: The clinical presentation and outcomes of COVID-19 during the first wave no longer represent COVID-19 in KRT patients, as the pandemic has become centred around vaccinated KT recipients. Vaccines lowered the incidence of diagnosed COVID-19 and mortality. However, mortality remains high despite increased access to ICU care.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

LAG3 genotype of the donor and clinical outcome after allogeneic transplantation from HLA-identical sibling donors

  • Cruz, David
  • Rodríguez-Romanos, Rocío
  • González-Bartulos, Marta
  • García-Cadenas, Irene
  • Cámara, Rafael de la
  • Heras, Inmaculada
  • Buño, Ismael
  • Santos, Nazly
  • Lloveras, Natàlia
  • Velarde, Pilar
  • Tuset, Esperanza
  • Martínez, Carmen
  • González, Marcos
  • Sanz, Guillermo F.
  • Ferrá, Christelle
  • Sampol, Antonia
  • Coll, Rosa
  • Pérez-Simón, José A.
  • López-Jiménez, Javier
  • Jurado, Manuel
  • Gallardo, David
  • GvHD/Immunotherapy Working Party of the Spanish Group of Hematopoietic Transplant (GETH)
© 2023 Cruz, Rodríguez-Romanos, González-Bartulos, García-Cadenas, de la Cámara, Heras, Buño, Santos, Lloveras, Velarde, Tuset, Martínez, González, Sanz, Ferrá, Sampol, Coll, Pérez-Simón, López-Jiménez, Jurado and Gallardo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms., Introduction: The association of polymorphisms in molecules involved in the immune response (checkpoint inhibitors) with the clinical outcome after allogeneic transplantation (alloHSCT) has been described. Lymphocyte Activation 3 (LAG3) is a surface protein that plays a regulatory role in immunity as an inhibitory immune checkpoint molecule., Methods: To determine its role in the alloHSCT setting, we analyzed 797 patients transplanted from HLA-identical sibling donors. The LAG3 rs870849 C>T polymorphism was genotyped in donors., Results: We detected a higher incidence of severe acute GVHD in patients transplanted from donors with TT genotype (p: 0.047, HR 1.64; 95% CI 1.01 – 2.67). Overall survival (OS) was worse for patients transplanted from donors with the rs870849 CT/TT genotype (0.020; HR, 1.44; 95% CI 1.06 – 1.96), as well as disease-free survival (DFS) (p: 0.002; HR 1.58, 95%CI: 1.18 – 2.14) and transplant-related mortality (TRM) (p< 0.001; HR: 1.88, 95% CI 1.29 – 2.74). When combining the LAG3 rs870849 and the PDCD1 rs36084323 genotypes of the donor, three genetic groups were well defined, allowing a good stratification of the risk of acute GVHD, TRM, OS and DFS., Discussion: We conclude that the LAG3 genotype of the donor may be considered in donors’ selection. As this selection may be limited in the HLA-identical sibling donor scenario, further studies exploring the impact of LAG3 genotype of the donor in unrelated transplantation are warranted., This work has been financed by grants PI17/00815 and PI20/01353, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Antifibrotic Agents for the Management of CKD: A Review

  • Ruiz-Ortega, Marta
  • Lamas Peláez, Santiago
  • Ortiz, Alberto
Kidney fibrosis is a hallmark of chronic kidney disease (CKD) and a potential therapeutic target. However, there are conceptual and practical challenges to directly targeting kidney fibrosis. Whether fibrosis is mainly a cause or a consequence of CKD progression has been disputed. It is unclear whether specifically targeting fibrosis is feasible in clinical practice because most drugs that decrease fibrosis in preclinical models target additional and often multiple pathogenic pathways (eg, renin-angiotensin-aldosterone system blockade). Moreover, tools to assess whole-kidney fibrosis in routine clinical practice are lacking. Pirfenidone, a drug used for idiopathic pulmonary fibrosis, is undergoing a phase 2 trial for kidney fibrosis. Other drugs in use or being tested for idiopathic pulmonary fibrosis (eg, nintedanib, PRM-151, epigallocatechin gallate) are also potential candidates to treat kidney fibrosis. Novel therapeutic approaches may include antagomirs (eg, lademirsen) or drugs targeting interleukin 11 or NKD2 (WNT signaling pathway inhibitor). Reversing the dysfunctional tubular cell metabolism that leads to kidney fibrosis offers additional therapeutic opportunities. However, any future drug targeting fibrosis of the kidneys should demonstrate added benefit to a standard of care that combines renin-angiotensin system with mineralocorticoid receptor (eg, finerenone) blockade or with sodium/glucose cotransporter 2 inhibitors., This work was supported by grants from Instituto de Salud Carlos III (ISCIII) and Fondos FEDER European Union (PI17/00119, PI20/00140, DTS20/00083, PI18/01366, PI19/00588, PI19/00815, DTS18/00032, Red de Investigacion Renal REDINREN: RD16/0009, RICORS2040 RD21/0005/0001) Comunidad Autonoma de Madrid FEDER-a way to build Europe (B2017/ BMD-3751 NOVELREN-CM to MR-O and SL); Convocatoria Dinamizacion Europa Investigacion 2019 ” MINECO (EIN2019-103294 to M.R-O B2017/BMD-3686 CIFRA2-CM to AO); Innovation programme under the Marie Skłodowska-Curie grant of the European Union’s Horizon 2020 (IMPROVE-PD ID: 812699) to MR-O; and ERA-PerMed-JTC2018 (KIDNEY ATTACK AC18/00064 and PERSTIGAN AC18/00071, Sociedad Espanola de Nefrología, FRIAT, Comunidad de Madrid en Biomedicina and Ministerio de Ciencia e Innovación: PID2019-104233RB-I00/AEI/10.13039/501100011033 to SL
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer

  • López de Maturana, Evangelina
  • Rodríguez, Juan Antonio
  • Alonso, Lola|||0000-0002-3493-718X
  • Lao, Oscar
  • Molina Montes, Esther|||0000-0002-0428-2426
  • Martín-Antoniano, Isabel Adoración
  • Gómez-Rubio, Paulina
  • Lawlor, Rita
  • Carrato, Alfredo|||0000-0001-7749-8140
  • Hidalgo, Manuel|||0000-0002-3765-3318
  • Iglesias, Mar|||0000-0002-2274-4671
  • Molero, Xavier|||0000-0003-2473-7405
  • Löhr, Matthias
  • Michalski, Christopher
  • Perea, José
  • O'Rorke, Michael
  • Barberà, Victor Manuel
  • Tardón, Adonina|||0000-0001-5150-1209
  • Farré, Antoni|||0000-0003-1279-8868
  • Muñoz-Bellvis, Luis|||0000-0002-7809-5201
  • Crnogorac-Jurcevic, Tanja
  • Domínguez-Muñoz, Enrique
  • Gress, Thomas
  • Greenhalf, William
  • Sharp, Linda
  • Arnes, Luís
  • Cecchini, Lluís|||0000-0002-8873-0969
  • Balsells Valls, Joaquim|||0000-0002-1202-4136
  • Costello, Eithne
  • Ilzarbe, Lucas|||0000-0003-1798-6876
  • Kleeff, Jörg
  • Kong, Bo
  • Márquez, Mirari
  • Mora Brugués, Josefina|||0000-0001-6777-5132
  • O'Driscoll, Damian
  • Scarpa, Aldo
  • Ye, Weimin
  • Yu, Jingru
  • García-Closas, Montserrat
  • Kogevinas, Manolis|||0000-0002-9605-0461
  • Rothman, Nathaniel
  • Silverman, Debra T.
  • Albanes, Demetrius
  • Arslan, Alan A.
  • Beane-Freeman, Laura
  • Bracci, Paige M.
  • Brennan, Paul
  • Bueno-de-Mesquita, Bas
  • Buring, Julie
  • Canzian, Federico|||0000-0002-4261-4583
  • Du, Margaret
  • Gallinger, Steven
  • Gaziano, J. Michael
  • Goodman, Phyllis J.
  • Gunter, Marc
  • LeMarchand, Loic
  • Li, Donghui
  • Neale, Rachael E.
  • Peters, Ulrike
  • Petersen, Gloria M.
  • Risch, Harvey A.
  • Sánchez Pérez, María José|||0000-0003-4817-0757
  • Shu, Xiao-Ou
  • Thornquist, Mark D.
  • Visvanathan, Kala
  • Zheng, Wei|||0000-0003-1226-070X
  • Chanock, Stephen|||0000-0002-2324-3393
  • Easton, Douglas F.|||0000-0003-2444-3247
  • Wolpin, Brian M.
  • Stolzenberg-Solomon, Rachael Z.
  • Klein, Alison P.
  • Amundadottir, Laufey T.|||0000-0003-1859-8971
  • Marti-Renom, Marc A.|||0000-0002-0151-4279
  • Real, Francisco X.|||0000-0001-9501-498X
  • Malats, Núria|||0000-0003-2538-3784
Pancreatic cancer (PC) is a complex disease in which both non-genetic and genetic factors interplay. To date, 40 GWAS hits have been associated with PC risk in individuals of European descent, explaining 4.1% of the phenotypic variance. We complemented a new conventional PC GWAS (1D) with genome spatial autocorrelation analysis (2D) permitting to prioritize low frequency variants not detected by GWAS. These were further expanded via Hi-C map (3D) interactions to gain additional insight into the inherited basis of PC. In silico functional analysis of public genomic information allowed prioritization of potentially relevant candidate variants. We identified several new variants located in genes for which there is experimental evidence of their implication in the biology and function of pancreatic acinar cells. Among them is a novel independent variant in NR5A2 (rs3790840) with a meta-analysis p value = 5.91E-06 in 1D approach and a Local Moran's Index (LMI) = 7.76 in 2D approach. We also identified a multi-hit region in CASC8 -a lncRNA associated with pancreatic carcinogenesis-with a lowest p value = 6.91E-05. Importantly, two new PC loci were identified both by 2D and 3D approaches: SIAH3 (LMI = 18.24), CTRB2/BCAR1 (LMI = 6.03), in addition to a chromatin interacting region in XBP1 -a major regulator of the ER stress and unfolded protein responses in acinar cells-identified by 3D; all of them with a strong in silico functional support. This multi-step strategy, combined with an in-depth in silico functional analysis, offers a comprehensive approach to advance the study of PC genetic susceptibility and could be applied to other diseases. The online version contains supplementary material available at 10.1186/s13073-020-00816-4.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

SGLT2 inhibitors for non-diabetic kidney disease, drugs to treat CKD that also improve glycaemia

  • Fernández-Fernández, Beatriz
  • Sarafidis, Pantelis|||0000-0002-9174-4018
  • Kanbay, Mehmet|||0000-0002-1297-0675
  • Navarro-González, Juan F.|||0000-0002-5015-7474
  • Soler, María José|||0000-0003-3621-0766
  • Górriz, Jose Luis|||0000-0002-1134-9051
  • Ortiz, Alberto|||0000-0002-9805-9523
Sodium-glucose co-transporter-2 (SGLT2) inhibitors decreased cardiovascular (CV) events and improved renal outcomes in CV safety studies in type 2 diabetes melitus (T2DM) patients at high CV risk. Canagliflozin also improved kidney outcomes in diabetic kidney disease in the Canagliflozin and Renal Events in Diabetes and Nephropathy Clinical Evaluationtrial. More recently, the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial showed that dapagliflozin improved CV outcomes in patients with HF with or without diabetes. Protection from HF in non-diabetics was confirmed for empagliflozin in the EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced) trial. A meta-analysis of DAPA-HF and EMPEROR-Reduced confirmed reductions in all-cause and CV death and the combined risk of CV death or worsening HF, as well as in the composite renal endpoint {hazard ratio [HR] 0.62 [95% confidence interval (CI) 0.43-0.90]} without differences based on the presence of diabetes or baseline estimated glomerular filtration rate (eGFR). Moreover, the Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease (DAPA-CKD) showed that dapagliflozin as an add-on over renin-angiotensin system blockade in patients with chronic kidney disease (CKD; with or without T2DM) reduced the HR for the primary endpoint (time to the first occurrence of ≥50% eGFR decline, end-stage kidney disease or renal or CV death) to 0.61 (95% CI 0.51-0.72) and for the secondary endpoints of worsening renal function or death from kidney failure [HR 0.56 (95% CI 0.45-0.68)], hospitalization for HF or CV death [HR 0.71 (95% CI 0.55-0.92)] and all-cause mortality [HR 0.69 (95% CI 0.53-0.88)]. These beneficial effects were consistent in patients with and without T2DM. In conclusion, SGLT2 inhibitors offer CV and kidney protection in both diabetic and non-diabetic CKD and, additionally, improve glycaemic control in T2DM, making them first-line therapy for CKD independent from diabetic status.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19

  • Fernández-Fernández, Beatriz
  • D'Marco, Luis|||0000-0003-0148-891X
  • Górriz, Jose Luis|||0000-0002-1134-9051
  • Jacobs-Cachá, Conxita|||0000-0003-2518-7847
  • Kanbay, Mehmet|||0000-0002-1297-0675
  • Luis-Lima, Sergio|||0000-0003-3540-8252
  • Porrini, Esteban
  • Sarafidis, Pantelis|||0000-0002-9174-4018
  • Soler, María José|||0000-0003-3621-0766
  • Ortiz, Alberto|||0000-0002-9805-9523
Hospital admissions and mortality from the Coronavirus disease 2019 (COVID-19) pandemic are spreading throughout the world, and second and third waves are thought to be likely. Risk factors for severe COVID-19 include diabetes, chronic kidney disease and cardiovascular disease. Currently, there is no vaccine and no approved therapy. Therapeutic approaches are aimed at preventing viral replication and spread, limiting the impact of the inflammatory overdrive (cytokine storm), preventing thromboembolic complications and replacing or supporting organ function. However, despite organ support, mortality is currently 65% for those receiving advanced respiratory support and 78% for those requiring renal replacement therapies. Thus, efforts should be made to provide adjuvant organ protection therapy. This may imply novel therapies in clinical development (e.g., the Fas ligand trap asunercept), but uptake of repurposed drugs already in clinical use may be faster. In this regard, sodium glucose co-transporter-2 (SGLT2) inhibitors were recently shown to protect the heart and kidney both within and outside of a diabetic milieu context. Further, preclinical data support a beneficial effect for the lung. We now discuss the potential benefits and risks of SGLT2 inhibitors in COVID-19 and an ongoing clinical trial testing the impact of dapagliflozin on outcomes in COVID-19 patients with respiratory failure
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Genetic kidney diseases as an underrecognized cause of chronic kidney disease, the key role of international registry reports

  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Furlano, Monica|||0000-0003-1025-3901
  • Ortiz, Alberto|||0000-0002-9805-9523
  • Ars, Elisabet|||0000-0002-4118-4358
Inherited kidney diseases (IKDs) are among the leading causes of early-onset chronic kidney disease (CKD) and are responsible for at least 10-15% of cases of kidney replacement therapy (KRT) in adults. Paediatric nephrologists are very aware of the high prevalence of IKDs among their patients, but this is not the case for adult nephrologists. Recent publications have demonstrated that monogenic diseases account for a significant percentage of adult cases of CKD. A substantial number of these patients have received a non-specific/incorrect diagnosis or a diagnosis of CKD of unknown aetiology, which precludes correct treatment, follow-up and genetic counselling. There are a number of reasons why genetic kidney diseases are difficult to diagnose in adulthood: (i) adult nephrologists, in general, are not knowledgeable about IKDs; (ii) existence of atypical phenotypes; (iii) genetic testing is not universally available; (iv) family history is not always available or may be negative; (v) lack of knowledge of various genotype-phenotype relationships and (vi) conflicting interpretation of the pathogenicity of many sequence variants. Registries can contribute to visualize the burden of IKDs by regularly grouping all IKDs in their annual reports, as is done for glomerulonephritis or interstitial diseases, rather than reporting only cystic disease and hiding other IKDs under labels such as 'miscellaneous' or 'other'. Any effort to reduce the percentage of patients needing KRT with a diagnosis of 'nephropathy of unknown etiology' or an unspecific/incorrect diagnosis should be encouraged as a step towards precision nephrology. Genetic testing may be of value in this context but should not be used indiscriminately, but rather on the basis of a deep knowledge of IKDs.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Novel strategies in nephrology, what to expect from the future?

  • Copur, Sidar
  • Tanriover, Cem
  • Yavuz, Furkan
  • Soler Aznar, Maria|||0000-0001-7232-2277
  • Ortiz, Alberto|||0000-0002-9805-9523
  • Covic, Adrian
  • Kanbay, Mehmet|||0000-0002-1297-0675
Chronic kidney disease (CKD) will become the fifth global case of death by 2040. Its largest impact is on premature mortality but the number of persons with kidney failure requiring renal replacement therapy (RRT) is also increasing dramatically. Current RRT is suboptimal due to the shortage of kidney donors and dismal outcomes associated with both hemodialysis and peritoneal dialysis. Kidney care needs a revolution. In this review, we provide an update on emerging knowledge and technologies that will allow an earlier diagnosis of CKD, addressing the current so-called blind spot (e.g. imaging and biomarkers), and improve renal replacement therapies (wearable artificial kidneys, xenotransplantation, stem cell-derived therapies, bioengineered and bio-artificial kidneys).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

LAG3 genotype of the donor and clinical outcome after allogeneic transplantation from HLA-identical sibling donors

  • Cruz, David
  • Rodríguez-Romanos, Rocío|||0000-0002-2827-7074
  • González-Bartulos, Marta
  • García Cadenas, Irene|||0000-0002-2994-9055
  • de la Camara, Rafael|||0000-0002-8189-5779
  • Heras, Inmaculada
  • Buño, Ismael|||0000-0003-4931-9170
  • Santos, Nazly
  • Lloveras, Natàlia|||0000-0002-9063-2241
  • Velarde, Pilar
  • Tuset, Esperanza|||0000-0002-1463-6689
  • Martínez, Carmen|||0000-0002-8401-7306
  • González, Marcos
  • Sanz, Guillermo F.
  • Ferrá, Christelle|||0000-0003-4571-5125
  • Sampol, Antonia|||0000-0001-7465-6203
  • Coll, Rosa|||0000-0003-0560-1254
  • Pérez-Simón, Jose A.
  • López-Jiménez, Javier
  • Jurado, Manuel|||0000-0001-9156-3797
  • Gallardo, David|||0000-0003-1615-4592
The association of polymorphisms in molecules involved in the immune response (checkpoint inhibitors) with the clinical outcome after allogeneic transplantation (alloHSCT) has been described. Lymphocyte Activation 3 (LAG3) is a surface protein that plays a regulatory role in immunity as an inhibitory immune checkpoint molecule. To determine its role in the alloHSCT setting, we analyzed 797 patients transplanted from HLA-identical sibling donors. The LAG3 rs870849 C.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Evolving spectrum but persistent high mortality of COVID-19 among patients on kidney replacement therapy in the vaccine era, the Spanish COVID-19 KRT Registry

  • Quiroga, Borja|||0000-0001-5730-1929
  • Ortiz, Alberto|||0000-0002-9805-9523
  • Cabezas-Reina, Carlos Jesús
  • Ruiz Fuentes, María Carmen
  • Jiménez, Verónica López
  • Larrondo, Sofía Zárraga
  • Toapanta, Néstor|||0000-0001-5983-6863
  • Gómez, María Molina
  • de Sequera, Patricia|||0000-0001-7705-9228
  • Sánchez-Álvarez, Emilio
Kidney replacement therapy (KRT) conferred a high risk for coronavirus disease 2019 (COVID-19) related mortality early in the pandemic. We evaluate the presentation, treatment and outcomes of COVID-19 in patients on KRT over time during the pandemic. This registry-based study involved 6080 dialysis and kidney transplant (KT) patients with COVID-19, representing roughly 10% of total Spanish KRT patients. Epidemiology, comorbidity, infection, vaccine status and treatment data were recorded, and predictors of hospital admission, intensive care unit (ICU) admission and mortality were evaluated. Vaccine introduction decreased the number of COVID-19 cases from 1747 to 280 per wave. Of 3856 (64%) COVID-19 KRT patients admitted to the hospital, 1481/3856 (38%) were admitted during the first of six waves. Independent predictors for admission included KT and the first wave. During follow-up, 1207 patients (21%) died, 500/1207 (41%) during the first wave. Among vaccinated patients, mortality was 19%, mostly affecting KT recipients. Overall, independent predictors for mortality were older age, disease severity (lymphopaenia, pneumonia) and ICU rejection. Among patient factors, older age, male sex, diabetes, KT and no angiotensin receptor blockers (ARB) were independent predictors of death. In KT recipients, individual immunosuppressants were independent predictors of death. Over time, patient characteristics evolved and in later pandemic waves, COVID-19 was mainly diagnosed in vaccinated KT recipients; in the few unvaccinated dialysis patients, ICU admissions increased and mortality decreased (28% for the first wave and 16-22% thereafter). The clinical presentation and outcomes of COVID-19 during the first wave no longer represent COVID-19 in KRT patients, as the pandemic has become centred around vaccinated KT recipients. Vaccines lowered the incidence of diagnosed COVID-19 and mortality. However, mortality remains high despite increased access to ICU care.